Epizyme Inc (NASDAQ:EPZM) – Analysts at Svb Leerink boosted their Q2 2019 EPS estimates for Epizyme in a note issued to investors on Monday, May 6th. Svb Leerink analyst A. Berens now anticipates that the biopharmaceutical company will post earnings per share of ($0.47) for the quarter, up from their previous forecast of ($0.55). Svb Leerink also issued estimates for Epizyme’s Q3 2019 earnings at ($0.46) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($2.44) EPS, FY2021 earnings at ($2.34) EPS, FY2022 earnings at ($1.80) EPS and FY2023 earnings at ($1.19) EPS.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.07. The company had revenue of $7.89 million for the quarter, compared to analyst estimates of $1.13 million.
Several other research analysts have also weighed in on the stock. Cowen reissued a “buy” rating and set a $18.00 price objective on shares of Epizyme in a report on Tuesday, February 26th. BidaskClub raised shares of Epizyme from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. Oppenheimer decreased their price target on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating for the company in a report on Wednesday, February 27th. ValuEngine lowered shares of Epizyme from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Epizyme in a report on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Epizyme has a consensus rating of “Buy” and an average price target of $18.90.
Shares of EPZM stock opened at $12.23 on Thursday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -7.11 and a beta of 3.08. Epizyme has a 1-year low of $5.14 and a 1-year high of $18.70.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Exane Derivatives acquired a new position in shares of Epizyme in the 1st quarter valued at about $84,000. Quantamental Technologies LLC bought a new stake in Epizyme in the 4th quarter valued at about $43,000. Legal & General Group Plc lifted its position in Epizyme by 16.9% in the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 1,455 shares during the last quarter. JGP Global Gestao de Recursos Ltda. bought a new stake in Epizyme in the 4th quarter valued at about $76,000. Finally, Two Sigma Advisers LP bought a new stake in Epizyme in the 4th quarter valued at about $76,000. 72.62% of the stock is owned by institutional investors and hedge funds.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
Recommended Story: How is net asset value different from market price?
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.